<DOC>
	<DOCNO>NCT00020878</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development cancer . Celecoxib may effective prevent lung cancer tobacco smoker . PURPOSE : Phase II trial study effectiveness celecoxib prevent non-small cell lung cancer tobacco smoker .</brief_summary>
	<brief_title>Celecoxib Preventing Non-Small Cell Lung Cancer Tobacco Smokers</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy feasibility celecoxib chemoprevention primary non-small cell lung cancer high-risk tobacco smoker . - Determine safety long-term side effect drug population . OUTLINE : Patients receive oral celecoxib twice daily 6 month . Patients follow 2 week 6 month . PROJECTED ACCRUAL : A total 20 patient accrue study within 6 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Age &gt; 45 Smoked &gt; 20 pack year Concurrent use NSAIDs Hypersensitivity celecoxib Documented allergictype reaction sulfonamides History allergic reaction , urticaria asthma aspirin NSAIDs History liver dysfunction Hypertension cardiac condition aggravate fluid retention edema Previous history gastrointestinal ulceration , bleeding , perforation Renal dysfunction End stage respiratory disease Unstable angina Other malignancy Pregnancy Concurrent use medication know alter affected alteration hepatic p450 2C9 2D6 enzyme Patents concurrent medical condition may interfere completion test , therapy , follow schedule</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>non-small cell lung cancer</keyword>
</DOC>